Join Drs. Rachel Batterham, Carel W. Le Roux and Marco Bueter as they discuss the latest news for treatment of bariatric patients with type 2 diabetes mellitus.
MD, MBBS, PhD, FRCP
Professor, Obesity, Diabetes and Endocrinology, University College London Hospital (UCLH); Head, UCLH/UCL National Institute of Health Research Biomedical Research Centre, London, United Kingdom
MBChB, MSC, FRCP, FRCPath, PhD
Professor, Imperial College London,
Professor, Head of Program for Bariatric and Metabolic Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerlan
Making the Case for Metabolic Surgery in Patients with Obesity and T2DM
This educational activity is intended for an international audience of non-US healthcare professionals, specifically diabetologists and endocrinologists, surgeons and primary care physicians involved in the treatment of patients with type 2 diabetes mellitus (T2DM).
Upon completion of this activity, participants will have increased knowledge regarding the:
• Science supporting bariatric interventions in the management of obesity and T2DM
• Clinical trial data for metabolic / bariatric surgery in the management of patients with obesity and T2DM
• Utility of metabolic / bariatric surgery vs the long-term risks of suboptimal treatment of obesity and T2DM
Purpose / Goal
The goal of this activity is to improve awareness of bariatric surgery vs pharmacotherapy in weight reduction and T2DM management, and in particular risk and benefits, and
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).
Commercial Support Acknowledgment
This educational activity is supported by an independent educational grant from Johnson & Johnson — Ethicon.
To learn more: